Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy. | Novo Nordisk and Hims & Hers have struck a truce after sparring over ...

Some telehealth companies that offered compounded GLP-1s have disappeared altogether. Others are pursuing strategies that ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.

Medicare coverage of obesity medications could drive a substantial rise in healthcare spending, according to a new study. A microsimulation model published in JAMA Health Forum projected that Medicare ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

In the past 20 years, the average rate of obesity among adults in the United States has risen by approximately 30 percent, but the rate of those with the most severe forms of obesity, or those with a ...

Wellness influencer Janelle Rohner reveals she is 'microdosing' GLP-1 medication for weight loss and addresses criticism over ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

Danuglipron is part of a class of drugs known as GLP-1 receptor agonists, which mimic gut hormones to regulate appetite and blood sugar. The category has become one of the hottest areas in the ...